Company Profile For Novo Nordisk A/S

Novo Nordisk A/S (NOVOb.CO) (Copenhagen Stock Exchange)

sector: Healthcare · industry: Pharmaceuticals - Generic & Specialty ·

As of 24 Nov 2009

322.75DKK

Price Change

-7.25

Percent Change

-2.20%

Analyst Recommendations

Overview

Novo Nordisk A/S is a Denmark-based healthcare company. The Company provides diabetes care and is engaged in haemostasis management, growth hormone therapy and hormone replacement therapy. The Company manufactures and markets pharmaceutical products and services to patients, the medical profession and society. The Company is organized in two segments: diabetes care and biopharmaceuticals. Diabetes care includes discovery, development, manufacturing and marketing of products within the areas of insulin, glucagon-like peptide (GLP)-1 and related delivery systems, as well as oral antidiabetic products (OAD). Biopharmaceuticals includes discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.

Quick Financial Synopsis

BRIEF: For the nine months ended 30 September 2009, Novo Nordisk A/S' revenue increased 15% to DKR38.02B. Net income for the period increased 15% to DKR8.45B. Revenue reflects anincrease in sales from all business segments and all geographical segments. Net income for the period reflects improved gross and operating margins, as well as decreased research and development costs and lower loss from share of associates.